Ramipril (all strengths): Supply issue

Supply issue Active

Due to problems at the factory, the supplier will run out of Tryzan brand ramipril capsules over the coming months.

Affected product

Over the coming months all strengths of Tryzan brand ramipril capsules will run out.

Strength Pharmacode Subsidy Measure / Qty Expected to run out
1.25 mg 2635747 $17.25 per 90 Early June 2026
2.5 mg 2635755 $16.50 per 90 Late July 2026
5 mg 2635763 $16.88 per 90 Mid-May 2026
10 mg 2635771 $17.63 per 90 Early May 2026

Alternative product

From 1 May, we are listing alternatives for the 1.25, 5, and 10 mg strengths. We are working on a listing for a 2.5 mg strength product. None of these brands have been approved by Medsafe, they will need to be prescribed and dispensed in line with section 29A of the Medicines Act. All brands are listed as section 29 and wastage is claimable.

Key differences:

  • Both Viatris and Mylan generics are tablets (the current brand is capsules).
  • Mylan generics comes in Italian packaging with an English sticker
  • The Viatris is a 30 pack, Mylan generics is a 28 pack, where the Tryzan brand is a 90 pack.

What's the same?

  • The same active ingredient, in the same amount
  • Designed to work in your body the same way
Strength Brand Pharmacode Subsidy Measure / Qty Date listed
1.25 mg Ramipril Viatris 2728192 $5.75 per 30 1 May 2026
2.5 mg TBC (to be confirmed) TBC  TBC TBC TBC (likely 1 June)
5 mg Ramipril Mylan generics 2727854 $5.25 per 28 1 May 2026
10 mg Ramipril Mylan generics 2727862 $5.48 per 28 1 May 2026
.
Boxes and blister pack images for the alternative brands

Flyers are available to download to support conversations with patients.

Prescribing and supplying an unapproved medicine

Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. 

We know supplying an unapproved medicine. In this case, however, this will allow people to continue to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 and 29A medicines – Medsafe website (external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)